Major depressive disorder (MDD) is associated with immune-inflammatory dysregulation and a state described as immune sensitization. The authors tested whether ketamine, applied in vitro to stimulated whole blood, attenuates PHA/LPS-induced immune sensitization in patients with MDD compared with healthy controls (HCs). The objective was to characterize concentration-dependent immunomodulatory effects of ketamine on cytokines, chemokines, growth factors, and composite immune profiles.
Whole blood samples were obtained from 18 patients diagnosed with MDD and 18 healthy control participants. Samples were stimulated with phytohemagglutinin (PHA) and lipopolysaccharide (LPS) to evoke an immune response and then incubated with ketamine at three concentrations: 0.3 μM, 0.6 μM, and 6 μM. Incubation lasted 72 hours. Measured outputs included a panel of cytokines, chemokines, and growth factors, and synthesized composite immune profiles to represent M1 and M2 macrophage activity, T helper subsets (Th1, Th2, Th17), the immune-inflammatory response system (IRS), and the compensatory immunoregulatory system (CIRS).
The study synthesized composite scores for key immune pathways: M1 and M2 macrophage phenotypes, Th1/Th2/Th17 responses, IRS and CIRS, as well as aggregated measures of chemokines and growth factors. Individual analytes reported in the source included IL-12(p70), MIP-1β, IL-1β, IFN-γ, IL-2, TNF-β, among others. The authors evaluated both group-level differences (MDD vs HC) and group-by-treatment interactions to determine whether ketamine’s effects varied by diagnosis.
Under PHA/LPS stimulation in this assay, the MDD group showed broadly elevated immune activity compared with HCs. Specifically, composite profiles for M1, M2, Th1, Th2, Th17, IRS, CIRS, chemokines, and growth factors were markedly higher in the MDD samples, consistent with a stimulus-evoked immune-sensitized phenotype.
Significant group-by-treatment interactions were observed for multiple outcomes, including the Th1–Th2 balance, M2 profile, growth factors, IL-12(p70), M1, and chemokines. These interactions indicate that ketamine affected stimulated immune responses differently in MDD samples versus HCs. Broadly, ketamine produced minimal changes in HC samples but caused wider suppression of stimulated immune markers in MDD samples, with the strongest effects seen at the highest concentration tested (6 μM). Despite this broader suppression in MDD, ketamine did not fully normalize the sensitized immune phenotype exhibited by the MDD group under stimulation.
Some immune markers showed decreases with ketamine that did not differ by diagnostic group, indicating diagnosis-independent effects. Compared with control (no ketamine) conditions, ketamine reduced levels of MIP-1β, IL-1β, Th1 measures, TNF-β, IRS, IFN-γ, and IL-2 across both MDD and HC samples. These findings suggest a broader immunosuppressive action of ketamine at stimulated conditions that is not restricted to samples from people with MDD.
The authors interpret the findings as demonstrating two distinct immunoregulatory patterns of ketamine in this in vitro stimulated whole-blood model. First, there is a selective, disease-dependent attenuation of pathways that are specifically sensitized in MDD (evidenced by group-by-treatment interactions). Second, there is a broader, diagnosis-independent suppression of several stimulated immune markers, particularly at higher ketamine concentrations. However, the study reports that these effects were insufficient to restore the exaggerated, sensitized immune phenotype in MDD to the level observed in HCs under identical stimulated conditions.
Limitations intrinsic to the reported experiment include the ex vivo design and the specific stimulation model (PHA/LPS), which reflect stimulated immune responses in whole blood but do not directly establish in vivo clinical effects. The source did not report any clinical outcomes, longitudinal data, or attempts to link these in vitro immune changes to symptomatic change in MDD.
The study was approved by the Ethics Committee of the University of Electronic Science and Technology of China (Approval No.: 30005). The authors stated that participant consent and reporting guidelines were followed. Data will be provided by the corresponding author upon request. The authors declared no competing interests.